Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer patients, has signed a commercialization agreement with EVERSANA, a global commercialization services provider, to gear up for the potential US launch of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk, localized prostate cancer.
Under the deal, EVERSANA will deliver an integrated range of services covering data and analytics, medical affairs, market access, and field operations.
EVERSANA joins IDEA Pharma, a division of SAI MedPartners, which has already been working with Candel on path-to-market strategies and positioning for aglatimagene.
The company said it has been collaborating closely with both partners across key pre-commercial workstreams.
The tie-up is part of Candel's broader partner-led commercial strategy, which the company says keeps it financially nimble while giving it access to seasoned commercial expertise as it works toward a potential regulatory approval.
"From the beginning, we designed Candel's commercial strategy around a partner-led model that allows us to stay focused on advancing the science and navigating the regulatory pathway, while having access to world-class commercial capabilities on demand," said Paul Peter Tak, CEO of Candel.
"With the addition of EVERSANA, that model is fully in place, and with the progress we’ve already made across our pre-commercialization workstreams, we have confidence in our readiness for the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer."
Gregory Skalicky, president of EVERSANA, said the two teams are already up and running together, with commercial workstreams actively underway. "Candel's unique approach to commercialization, building a dedicated and flexible platform with specialized partners rather than a fixed pharmaceutical infrastructure, is exactly the type of model EVERSANA was designed to support," he said.
Any commercial launch of aglatimagene remains subject to regulatory approval.